Loading
Cancer Risks and Factors / Esophageal Cancer Research and Treatment · Journal article
Scientific Reports · September 8, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study of 286 patients demonstrates that high BMI is an independent predictor of superior overall survival, progression-free survival, and objective response rates to anti-PD-1 immunotherapy in locally advanced or metastatic esophageal cancer, with associations mediated by favorable immune profiles. A validated nomogram incorporating BMI, gender, TNM stage, and pan-immune inflammation value showed high predictive accuracy at 24 and 36 months in internal and external cohorts. The finding supports the emerging 'obesity paradox' in immunotherapy but requires prospective confirmation and mechanistic validation.
Retrospective cohort study with internal and external validation. 286 eligible patients with locally advanced or metastatic esophageal cancer receiving anti-PD-1 immunotherapy across two medical centers. Intervention: Anti-PD-1 inhibitor-based immunotherapy. Compared with: Stratified comparison by BMI category and metabolic syndrome status; no unexposed control group. n = 286. Two medical centers; specific countries or regions not stated.
Patients with high BMI demonstrated significantly superior overall survival, progression-free survival, and objective response rates to anti-PD-1 therapy High BMI and metabolic syndrome groups exhibited lower pan-immune inflammation value (PIV) and higher combined positive score (CPS) Prognostic nomogram incorporating gender, BMI, TNM stage, and PIV demonstrated high predictive accuracy for 24- and 36-month overall survival in both internal and external validation cohorts
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings challenge conventional assumptions about obesity in cancer and suggest that elevated BMI may serve as a metabolic biomarker predicting superior response to checkpoint inhibitor immunotherapy in esophageal cancer. The validated nomogram could support prognostic counseling, though the observational design limits causal inference and prospective studies are needed before incorporating BMI as a treatment selection criterion.
A sound retrospective cohort study with internal and external validation showing that high BMI predicts superior immunotherapy outcomes in esophageal cancer, but limited by observational design, modest sample size, and reliance on surrogate endpoints rather than hard clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
These findings challenge conventional assumptions about obesity in cancer and suggest that elevated BMI may serve as a metabolic biomarker predicting superior response to checkpoint inhibitor immunotherapy in esophageal cancer. The validated nomogram could support prognostic counseling, though the observational design limits causal inference and prospective studies are needed before incorporating BMI as a treatment selection criterion.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
INTRODUCTION: PD-1 inhibitor-based immunotherapy is increasingly used for locally advanced or metastatic esophageal cancer, yet the impact of metabolic factors-including the emerging "obesity paradox", wherein high-body mass index (BMI) patients demonstrate a lower risk of all-cause cancer mortality and superior immunotherapy efficacy compared to those with a low-to-normal BMI-on treatment efficacy remains largely unknown. Patients were stratified by BMI and metabolic syndrome (MetS) to assess survival and treatment response; a prognostic nomogram was subsequently developed via LASSO and multivariable Cox regression and validated internally and externally using the respective institutional cohorts. A total of 286 eligible patients with locally advanced or metastatic esophageal cancer from two medical centers were included. Patients with high BMI or MetS demonstrated significantly superior overall survival, progression-free survival, and objective response rates to anti-PD-1 therapy. These groups exhibited favorable immune profiles, characterized by a lower pan-immune inflammation value (PIV) and a higher combined positive score (CPS). A prognostic nomogram was successfully constructed and validated, incorporating four independent predictors: gender, BMI, TNM stage, and PIV. The model demonstrated high predictive accuracy for 24- and 36-month overall survival in both internal and external validation cohorts, with well-fitted calibration curves. Elevated BMI serves as an independent predictor of improved outcomes following immunotherapy in locally advanced or metastatic esophageal cancer, whereas the prognostic trend of MetS appears largely dependent on body mass. Furthermore, our validated nomogram integrates these nutritional and metabolic profiles to enable refined prognostic assessment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.